Amgen to acquire Rodeo Therapeutics for USD 55 Million Upfront
Amgen Inc. and Rodeo Therapeutics Corporation announced a deal under which Amgen will take over Rodeo, a privately-held biopharmaceutical company based in Seattle, which develops small-molecule therapies to enhance regeneration and repair of several tissues. Rodeo's 15-PGDH program is a robust strategic fit with Amgen's inflammation portfolio and efforts to develop first-in-class therapeutics for patients.
Under terms of the deal, Amgen will acquire all outstanding shares of Rodeo in exchange for a USD 55 million upfront payment and future contingent milestone payments potentially worth up to a...
